Products with Anti-inflammatory bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5699 | Syringic acid |
| Syringic acid is a potential antioxidant used in traditional Chinese medicine and is an emerging nutraceutical. It has potential anti-angiogenic, anti-glycating, anti-hyperglycaemic,antimicrobial, fungitoxicity, neuroprotective, antimitogenic, chemo-sensitizing, anti-obesity, anti-inflammatory, anti-steatotic, and memory-enhancing properties. Syringic acid can ameliorate L-arginine methyl ester-induced hypertension by reducing oxidative stress, and can reduce the pancreatic damage induced by alloxan and stimulated β-cell regeneration in diabetic rats. Syringic acid can suppress hepatic fibrosis in chronic liver injury, it inhibits the activation of cultured hepatic stellate cells. | |
| BCN5702 | Euscaphic acid |
| 1. Euscaphic acid has anti-diabetic activity. 2. Euscaphic acid induces death by activation of caspase-3, dependent apoptotic pathway. 3. Euscaphic acid and tormentic acid have inhibitory effect on high fat diet-induced obesity in the rat. 4. Euscaphic acid has anti-contraction effects on rat’s aortic smooth muscle. 5. Euscaphic acid has anti-inflammatory activity, inhibits LPS-induced inflammatory responses by interference with the clustering of TRAF6 with IRAK1 and TAK1, resulting in blocking the activation of IKK and MAPKs signal transduction to downregulate NF-κB activations. | |
| BCN5717 | Aristolactam BII |
| 1. Aristolactam BII exerts its significant neuroprotective effects on glutamate-injured primary cultures of rat cortical cells by directly inhibiting the production of nitric oxide. 2. Aristolactam BII exhibits antimicrobial and antiinflammatory activity. 3. Aristolactam BII shows significant activity towards DPPH radical scavenging and potent inhibitory effects against tyrosinase mushroom. | |
| BCN5724 | Uvaol |
| Uvaol has anti-inflammatory, anti-proliferative, and vasorelaxing activities. Uvaol reduces cardiac hypertrophy and left ventricle remodeling induced by angiotensin II in mice by diminishing fibrosis and myocyte area; it inhibits the angiotensin II-induced proliferation in a PPAR-γ-dependent manner, while at high doses they activate pathways of programmed cell death that are dependent on JNK and PPAR-γ. | |
| BCN5725 | Lupeol |
| 1. Lupeol has a potential to act as an anti-inflammatory, anti-microbial, anti-protozoal, anti-proliferative, anti-invasive, anti-angiogenic, antimalarial and cholesterol lowering agent. 2. Lupeol prevents acetaminophen-induced in vivo hepatotoxicity by altering the Bax/Bcl-2 and oxidative stress-mediated mitochondrial signaling cascade. 3. Lupeol and its ester derivative have beneficial effects on hypercholesterolemia-induced oxidative and inflammatory stresses. 4. Lupeol significantly enhances the radiosensitivity of SMMC-7721 cells in vitro and in vivo. 5. Lupeol shows antidiabetic and antioxidant potential in experimental hyperglycaemia. 6. Lupeol has potential anticancer effect against hepatocellular and pancreatic cancer, by inhibiting cell proliferation, inducing apoptosis and blocking Akt/PI3K and Wnt signaling pathway. 7. Lupeol has antiangiogenic effects, it (at 50 and 30 microg/mL) shows a marked inhibitory activity on human umbilical venous endothelial cells (HUVEC) tube formation while it does not affect the growth of tumor cell lines such as SK-MEL-2, A549, and B16-F10 melanoma. | |
